DRUG
NNC0487-0111
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity
Status
Recruiting
Phase
Phase 1
Enrollment
120
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this clinical study is to look at if/how much NNC0487-0111 affects food intake, appetite and metabolism in participants with obesity when compared to placebo. There are 2 study treatments in this study. Participants will inject the study treatment under the skin of your stomach once a week. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants will get is decided by chance.
Interventions
Treatment arms and agents.
DRUG
Placebo (matched to NNC0487-0111)
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors into a skin fold on the abdomen.
Timeline
From registration to results.
First posted
Apr 2, 2026
Study start
Mar 30, 2026
Primary completion
Jan 19, 2028
Study completion
Jan 22, 2028
Results posted
Not reported
Registry updated
Apr 27, 2026
Outcomes
What the study measures.
Primary outcomes
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Time frame · From Baseline to Day 126
Measured as percentage change of energy.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Time frame · From Baseline to Day 182
Measured as percentage change of energy.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Time frame · From Baseline to Day 238
Measured as percentage change of energy.
Secondary outcomes
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Time frame · From Baseline to Day 126
Measured as kilojoules (kJ).
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Time frame · From Baseline to Day 182
Measured as kJ.
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Time frame · From Baseline to Day 238
Measured as kJ.
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 126
Time frame · From Baseline to Day 126
Measured as grams.
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 182
Time frame · From Baseline to Day 182
Measured as grams.
Change from baseline in total amount of food consumed across ad libitum breakfast, lunch, evening meal and snack box to Day 238
Time frame · From Baseline to Day 238
Measured as grams.
Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 378
Time frame · From Baseline to Day 378
Measured as percentage change of energy.
Change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 378
Time frame · From Baseline to Day 378
Measured as kJ.
Change from baseline in total amount of food consumed during ad libitum breakfast, lunch, evening meal and snack box to Day 378
Time frame · From Baseline to Day 378
Measured as grams.
Change from baseline in energy intake of high fat, sweet food during ad libitum energy intake in the evening snack box to Day 126
Time frame · From Baseline to Day 126
Measured as kJ.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 64 Years
- Sex
- ALL
- Healthy volunteers
- No
Key Inclusion Criteria: * Male or female (sex at birth). * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. * Overweight should be due to excess adipose tissue, as judged by the investigator. Key Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method. * History of type 1 or type 2 diabetes mellitus. * Glycated hemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole \[mmol/mol\]) at screening. * Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and/or amylin-based therapy due to tolerability issues. * Any clinically significant body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening. * Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.
Study locations
1 registered sites.
Germany. Showing up to 24 locations stored in the fast local snapshot.
Parexel International GmbH
Berlin, Germany
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Amycretin.
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk · Obesity · Heart Failure
Phase 3
Recruiting
5,610
2026-07
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Novo Nordisk · Obesity
Phase 3
Recruiting
1,150
2026-07
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk · Obesity · Knee Osteoarthritis (OA)
Phase 3
Recruiting
400
2026-07
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Novo Nordisk · Obesity
Phase 3
Recruiting
600
2026-07
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
400
2026-07
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk · Diabetes Mellitus · Overweight
Phase 3
Recruiting
630
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.